ESMO 2019 RT po RP - Badanie kliniczne RADICALS-RT

ESMO 2019 RT po RP - Badanie kliniczne RADICALS-RT

Nieprzeczytany postautor: zosia bluszcz » 04 paź 2019, 13:52

Men with Prostate Cancer can be Spared Radiotherapy after Surgery
[ESMO 2019 Press Release]
Date: 27 Sep 2019

Men with prostate cancer can be spared radiotherapy after surgery, according to late breaking results of the RADICALS-RT trial presented at the ESMO Congress 2019 in Barcelona, Spain. (1) The study answers a longstanding question about whether the benefits of radiotherapy after surgery outweigh the side-effects.

RADICALS-RT is the largest ever trial of postoperative radiotherapy in prostate cancer. It found no difference in disease recurrence at five years between men who routinely had radiotherapy shortly after surgery and men who had radiotherapy later, if the cancer came back.


Study first author Prof Chris Parker, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK said: “The results suggest that radiotherapy is equally effective whether it is given to all men shortly after surgery or given later to those men with recurrent disease. There is a strong case now that observation should be the standard approach after surgery and radiotherapy should only be used if the cancer comes back.”

“The good news is that in future, many men will avoid the side-effects of radiotherapy,” added Parker. “These include urinary leakage and narrowing of the urethra, which can make urination difficult. Both are potential complications after surgery alone, but the risk is increased if radiotherapy is used as well.”


The findings were confirmed in a collaborative meta-analysis, also presented at the ESMO Congress 2019, combining results of RADICALS with two similar trials, RAVES and GETUG-AFU17. (2) Author of the analysis, Dr Claire Vale, MRC Clinical Trials Unit, University College London, UK, said: “Results of the ARTISTIC meta-analysis confirm those of RADICALS, and provide greater evidence to support the routine use of observation and early salvage radiotherapy.”

“The meta-analysis provides the best opportunity to assess whether adjuvant radiotherapy may still have a role in some groups of men, and to investigate longer term outcomes,” added Vale.


Commenting on the data, Dr Xavier Maldonado, Hospital Universitari Vall d’Hebron, Barcelona, said: “These are the first results to suggest that postoperative radiotherapy for prostate cancer could be omitted or delayed in some patients. This will shorten the duration of treatment for these patients and allow better use of resources since today’s radiotherapy is technically sophisticated and therefore expensive. However, strict follow-up will be needed to identify patients requiring salvage radiotherapy.”

Maldonado noted that longer follow-up is needed for the main endpoint of RADICALS-RT, which is freedom from distant metastases at ten years, and to comprehensively report on toxicities.

Regarding the need for future research, Maldonado said the focus should be pinpointing which patients still require adjuvant radiotherapy to avoid a very early local relapse and potential subsequent metastases. “We need to develop genomic classifiers to help decide the best management strategy for each patient – whether it should include surgery and/or radiotherapy, and at which time points,” he said.


Results of RADICALS-RT

RADICALS-RT (NCT00541047) enrolled 1,396 patients after surgery for prostate cancer from the UK, Denmark, Canada, and Ireland. Men were randomly allocated to postoperative radiotherapy or the standard approach of observation only, with radiotherapy kept as an option if the disease recurred.

At a median follow-up of five years, progression free survival was 85% in the radiotherapy group and 88% in the standard care group (hazard ratio
1.10; 95% confidence interval [CI] 0.81–1.49; p=0.56).

Self-reported urinary incontinence was worse at one year in 5.3% of patients receiving radiotherapy compared to 2.7% who had standard care (p=0.008).
Radiation Therapy Oncology Group (RTOG) grade 3/4 urethral stricture was reported at any time in 8% versus 5% of the radiotherapy and standard care groups, respectively (p=0.03). Longer follow-up is needed to report on survival and on the primary outcome of freedom from distant metastases.



Results of the ARTISTIC meta-analysis

The ARTISTIC collaboration meta-analysis included three randomised trials comparing adjuvant radiotherapy with early salvage radiotherapy following prostatectomy for men with localised prostate cancer: RADICALS (ISRCTN40814031), GETUG-AFU 17 (NCT00667069), and RAVES (NCT00860652).The analysis was planned before the results of the trials were known.

The results are based on all 2,151 men included in the three trials, of whom 1,074 were randomised to adjuvant radiotherapy and 1,077 men were randomised to early salvage radiotherapy – of those, 395 men (37%) have commenced salvage treatment to date.

The analysis found no evidence that adjuvant radiotherapy improves event free survival compared to early salvage radiotherapy (HR 1.09; 95% CI 0.86–1.39; p=0.47). Based on these results, the difference in five-year event free survival is likely only to be around 1%.

Official Congress Hashtag: #ESMO19


https://www.esmo.org/Press-Office/Press ... arker-Vale
Obrazek
zosia bluszcz
Złoty Gladiator
Złoty Gladiator
 
Posty: 8794
Rejestracja: 13 cze 2009, 02:06
Blog: Wyświetl blog (0)

Re: ESMO 2019 RT po RP - Badanie kliniczne RADICALS-RT

Nieprzeczytany postautor: aqq » 04 paź 2019, 21:03

Jest w tym badaniu kilka kruczków, o czym w tej relacji nie napisano (m.in kryteria kwalifikacji znacząco odbiegające od obecnych wytycznych, które mogły zaburzyć wyniki - np. pT3a, wyjściowe PSA>10ng/ml, Gleason ≥7).
Z uwagi na zjazdowy charakter doniesienia, wstrzymałbym się do publikacji dokładnych wyników, analizą podgrup według czynników ryzyka, bo to może być znacznie ciekawsze.


To o czym pisałem wyżej ze strony badania - wiele może się wyjaśnić, jeśli okaże się, że główna masa chorych nie spełnia obecnych kryteriów kwalifikacji do adjuwantowej radioterapii.

"Inclusion
Post-operative serum PSA ≤0.2ng/ml
More than 4 weeks and less than 22 weeks after radical prostatectomy
One or more of:
pT3/4
Gleason 7-10 (biopsy or surgical sample)
Pre-operative PSA ≥10ng/ml
Positive margins"
A. de Saint-Exupery "Jeśli nie chcesz mieć swego udziału w klęskach, nie będziesz go miał również w zwycięstwach."
Awatar użytkownika
aqq
Złoty Gladiator
Złoty Gladiator
 
Posty: 387
Rejestracja: 03 sie 2012, 20:29
Lokalizacja: Zamość (od 2016), Kraków (2002-2016)
Blog: Wyświetl blog (0)


Wróć do O czym powinniśmy wiedzieć przed, w trakcie, po leczeniu

Kto jest online

Użytkownicy przeglądający to forum: Obecnie na forum nie ma żadnego zarejestrowanego użytkownika i 4 gości

logo zenbox